ClinicalTrials.gg
CompletedNCT03412565Updated Apr 29, 2025Results posted

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

A Phase 2 interventional study of Daratumumab and Bortezomib in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 64 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
265
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies in Multiple Myeloma by Johnson & Johnson — 13 open to participants now, 33 under way, 12 of them phase 3. Multiple Myeloma · Johnson & Johnson.

Enrollment
25th of 100
265 · median 125
Started
2018
with 2 others
Phase 2
32 of 126
4 open now
Registered
76th of 126
by date

Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 25th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2018, is one of 32 in phase 2, and was the 76th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 126 studies in Multiple Myeloma by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Multiple Myeloma by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.

Read the detailed description

The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected for albumin. Safety will be measured by adverse events, laboratory test results, electrocardiogram (ECGs), vital sign measurements, physical examination findings, SC injection-site assessments, and assessment of Eastern Cooperative Oncology Group (ECOG) performance status score. Study will consist of 3 phases (screening, treatment and follow-up) and duration of study is approximately 3 years.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Multiple myeloma diagnosed according to the International Myeloma Working Group (IMWG) diagnostic criteria
  • Measurable, secretory disease as defined by any of the following:

    1. Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL); or
    2. Urine M-protein level >= 200 milligram per 24 hours (mg/24 hours); or
    3. Light chain multiple myeloma (MM), for participants without in the serum or urine: serum Immunoglobulin (Ig) free light chain (FLC) >= 10 mg/dL and abnormal FLC ratio
  • Meets one of the sets of the following criteria:

    1. For Daratumumab + bortezomib + lenalidomide + dexamethasone (D-VRd) and Daratumumab + bortezomib + melphalan + prednisone + dexamethasone (D-VMP) regimen: newly diagnosed myeloma
    2. For Daratumumab + lenalidomide + dexamethasone (D-Rd) and Daratumumab + Carfilzomib + Dexamethasone (D-Kd) regimen: disease
    3. D-Kd cohort: Participants must have received only 1 for MM which included at least 2 consecutive cycles of lenalidomide therapy
  • (ECOG) Performance Status grade of 0, 1, or 2
  • During the study, during dose interruptions, and for 3 months after receiving the last dose of any component of the study treatment, a female participant must agree not to donate eggs (ova, oocytes) and male participants of must not donate semen or sperm during the study, during dose interruptions, or for 3 months after the last dose of any study drug

Exclusion criteria

Exclusion Criteria:

  • History of (other than MM) unless all treatment of that malignancy was completed at least 2 years before consent and the participant has no evidence of disease further exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years
  • Exhibits clinical signs of meningeal involvement of MM
  • Either of the following: a) with a (FEV1) is less than (\<) 50 percentage (%) of predicted normal b) Moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification c) For D-Kd cohort: Known infiltrative pulmonary disease or known pulmonary hypertension
  • Any of the following: a) Known to be seropositive for ; b) Seropositive for (defined by a positive test for hepatitis B surface antigen [HBsAg]). Participants with resolved infection (participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen [Anti-HBc] and/or antibodies to hepatitis B surface antigen [Anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are polymerase chain reaction (PCR) positive will be excluded
  • Known to be seropositive for (Anti-HCV antibody positive or HCV-RNA quantitation positive) except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy
  • For D-Kd cohort only: Transthoracic echocardiogram showing (LVEF) \<40%; uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic >99 mmHg despite optimal treatment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)

    Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m\^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.

    Drug: Daratumumab · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    D + Bortezomib + Melphalan + Prednisone (D-VMP)

    Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m\^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m\^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m\^2 orally on Days 1 to 4 of cycles 1 to 9.

    Drug: Daratumumab · Drug: Bortezomib · Drug: Melphalan · Drug: Prednisone

  • Experimental
    Daratumumab + Lenalidomide + Dexamethasone (D-Rd)

    Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.

    Drug: Daratumumab · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Daratumumab + Carfilzomib + Dexamethasone (D-Kd)

    Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m\^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.

    Drug: Daratumumab · Drug: Dexamethasone · Drug: Carfilzomib

Interventions

  • Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.

  • Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.

  • Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.

  • Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.

  • Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.

  • Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.

  • Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.

06

What researchers measure

Primary outcomes

  1. D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg) per 24 hours, If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: Up to 2 years 3 months

  2. D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response

    VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response \[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.

    Time frame: Up to 2 years and 3 months

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Daratumumab

    Cmax was defined as maximum serum concentration observed following daratumumab administration. Each cycle for: D-VRd cohort is of 21 days, D-VMP cohort is of 42 days and D-Rd and D-Kd cohorts is of 28 days. Each cohort have a treatment period of 84 days.

    Time frame: D-VRd: Day 4 of Cycles 1 and 4 and post treatment at Week 8; D-VMP: Day 4 of Cycles 1 and 2 and post treatment at Week 8; D-Rd and D-Kd: Day 4 of Cycles 1 and 3 and post treatment at Week 8

  2. Percentage of Participants With Infusion-Related Reactions (IRRs)

    Percentage of Participants with IRRs were reported. The administration-related systemic reactions are referred to as IRRs.

    Time frame: For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months

  3. D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response

    VGPR or better rate was defined as the percentage of participants who achieved VGPR or CR (including sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.

    Time frame: From baseline up to 2 years 7 months

  4. D-VRd Cohort: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved a PR or better, IMWG criteria, during the study or during follow up. IMWG criteria for PR \>= 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: Up to 2 years and 3 months

  5. Percentage of Participants With CR or Better Response

    CR or better rate was defined as the percentage of participants with a CR or better response (that is, CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal FLC ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.

    Time frame: For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months

  6. D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)

    DOR was defined as the time from the date of initial documented response (PR or better response) to the date of first documented evidence of progressive disease (PD) or death due to PD. PD is defined as an increase of 25% from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>=0.5 gram per deciliter \[g/dL\] and \>=200 mg/24 hours respectively); only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: From baseline up to 2 years 7 months

  7. Percentage of Participants With Anti-Daratumumab Antibodies

    Percentage of participants with antibodies to daratumumab were reported.

    Time frame: For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months

  8. Percentage of Participants With Anti-rHuPH20 Antibodies

    Percentage of participants with antibodies to rHuPH20 were reported.

    Time frame: For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months

  9. D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate

    MRD negativity rate was defined as the percentage of participants who were considered MRD negative after MRD testing at any timepoint after the first dose by bone marrow aspirate. MRD negativity rate was assessed by next-generation sequencing at a threshold of \<10\^5.

    Time frame: Up to 2 years and 3 months

07

Results

Posted Jan 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
Started67676566
Completed66191415
Not completed1485151
Withdrew: Lost to follow-up0010
Withdrew: Physician decision0001
Withdrew: Withdrawal by subject0455
Withdrew: Death1345
Withdrew: Data collection ended0414140

Outcome measures

PrimaryD-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg) per 24 hours, If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
Up to 2 years 3 months
Reported as:
Number · percentage of participants
D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)
percentage of participantsD + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)88.1 (79.5 to 93.9)90.8 (82.6 to 95.9)84.8 (75.7 to 91.5)
PrimaryD-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response

VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response \[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.

Time frame:
Up to 2 years and 3 months
Reported as:
Number · percentage of participants
D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response
percentage of participantsDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)
D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response71.6 (61.2 to 80.6)
SecondaryMaximum Observed Serum Concentration (Cmax) of Daratumumab

Cmax was defined as maximum serum concentration observed following daratumumab administration. Each cycle for: D-VRd cohort is of 21 days, D-VMP cohort is of 42 days and D-Rd and D-Kd cohorts is of 28 days. Each cohort have a treatment period of 84 days.

Time frame:
D-VRd: Day 4 of Cycles 1 and 4 and post treatment at Week 8; D-VMP: Day 4 of Cycles 1 and 2 and post treatment at Week 8; D-Rd and D-Kd: Day 4 of Cycles 1 and 3 and post treatment at Week 8
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Maximum Observed Serum Concentration (Cmax) of Daratumumab
micrograms per milliliter (mcg/mL)Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
Cycle 1 Day 4100 ± 48.598.6 ± 51.6108 ± 49.9137 ± 56.7
Cycle 2 Day 4—612 ± 256——
Cycle 3 Day 4——648 ± 238869 ± 274
Cycle 4 Day 4746 ± 275———
Post-treatment Phase Week 8263 ± 190162 ± NA—49.3 ± 109
SecondaryPercentage of Participants With Infusion-Related Reactions (IRRs)

Percentage of Participants with IRRs were reported. The administration-related systemic reactions are referred to as IRRs.

Time frame:
For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
Reported as:
Number · percentage of participants
Percentage of Participants With Infusion-Related Reactions (IRRs)
percentage of participantsDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
Percentage of Participants With Infusion-Related Reactions (IRRs)9.0 (4.0 to 16.9)9.0 (4.0 to 16.9)4.6 (1.3 to 11.5)4.5 (1.3 to 11.3)
SecondaryD-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response

VGPR or better rate was defined as the percentage of participants who achieved VGPR or CR (including sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.

Time frame:
From baseline up to 2 years 7 months
Reported as:
Number · percentage of participants
D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response
percentage of participantsD + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response77.6 (67.6 to 85.7)80.0 (70.1 to 87.7)77.3 (67.2 to 85.4)
SecondaryD-VRd Cohort: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved a PR or better, IMWG criteria, during the study or during follow up. IMWG criteria for PR \>= 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
Up to 2 years and 3 months
Reported as:
Number · percentage of participants
D-VRd Cohort: Overall Response Rate (ORR)
percentage of participantsDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)
D-VRd Cohort: Overall Response Rate (ORR)97.0 (90.9 to 99.5)
SecondaryPercentage of Participants With CR or Better Response

CR or better rate was defined as the percentage of participants with a CR or better response (that is, CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal FLC ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.

Time frame:
For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
Reported as:
Number · percentage of participants
Percentage of Participants With CR or Better Response
percentage of participantsDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
Percentage of Participants With CR or Better Response16.4 (9.5 to 25.7)55.2 (44.5 to 65.6)50.8 (39.9 to 61.5)42.4 (32.1 to 53.3)
SecondaryD-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)

DOR was defined as the time from the date of initial documented response (PR or better response) to the date of first documented evidence of progressive disease (PD) or death due to PD. PD is defined as an increase of 25% from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>=0.5 gram per deciliter \[g/dL\] and \>=200 mg/24 hours respectively); only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
From baseline up to 2 years 7 months
Reported as:
Median · months
D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)
monthsD + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Anti-Daratumumab Antibodies

Percentage of participants with antibodies to daratumumab were reported.

Time frame:
For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Daratumumab Antibodies
percentage of participantsDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
Percentage of Participants With Anti-Daratumumab Antibodies0000
SecondaryPercentage of Participants With Anti-rHuPH20 Antibodies

Percentage of participants with antibodies to rHuPH20 were reported.

Time frame:
For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-rHuPH20 Antibodies
percentage of participantsDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
Percentage of Participants With Anti-rHuPH20 Antibodies6.13.14.84.7
SecondaryD-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate

MRD negativity rate was defined as the percentage of participants who were considered MRD negative after MRD testing at any timepoint after the first dose by bone marrow aspirate. MRD negativity rate was assessed by next-generation sequencing at a threshold of \<10\^5.

Time frame:
Up to 2 years and 3 months
Reported as:
Number · percentage of participants
D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate
percentage of participantsD + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate25.4 (16.9 to 35.6)21.5 (13.5 to 31.6)27.3 (18.4 to 37.7)

Adverse events

Collected over For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)1/67 (1.5%)19/67 (28.4%)67/67 (100%)
D + Bortezomib + Melphalan + Prednisone (D-VMP)3/67 (4.5%)30/67 (44.8%)67/67 (100%)
Daratumumab + Lenalidomide + Dexamethasone (D-Rd)4/65 (6.2%)37/65 (56.9%)65/65 (100%)
Daratumumab + Carfilzomib + Dexamethasone (D-Kd)5/66 (7.6%)22/66 (33.3%)66/66 (100%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
PneumoniaInfections and infestations1/676/679/653/66
DiarrhoeaGastrointestinal disorders0/671/675/650/66
PyrexiaGeneral disorders4/675/673/652/66
InfluenzaInfections and infestations0/671/674/651/66
NeutropeniaBlood and lymphatic system disorders0/670/673/650/66
Cardiac FailureCardiac disorders0/672/673/651/66
Lower Respiratory Tract InfectionInfections and infestations1/670/673/650/66
Upper Respiratory Tract InfectionInfections and infestations0/670/673/650/66
Acute Kidney InjuryRenal and urinary disorders0/672/673/650/66
SepsisInfections and infestations0/670/672/651/66
Most frequent other events
Showing 10 of 84
Most frequent other events
EventDaratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
NeutropeniaBlood and lymphatic system disorders25/6730/6744/6515/66
ThrombocytopeniaBlood and lymphatic system disorders25/6738/6723/6534/66
DiarrhoeaGastrointestinal disorders16/6723/6732/6520/66
AnaemiaBlood and lymphatic system disorders12/6730/6726/6525/66
ConstipationGastrointestinal disorders26/6730/6721/656/66
Peripheral Sensory NeuropathyNervous system disorders28/6726/6714/657/66
InsomniaPsychiatric disorders12/6716/6713/6523/66
HypertensionVascular disorders1/6710/678/6523/66
NauseaGastrointestinal disorders12/6723/678/6517/66
PyrexiaGeneral disorders22/6722/6716/6514/66

Baseline characteristics

Age, Continuous
Age, Continuous(years)Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)Total
Mean57.3 ± 9.4774.9 ± 4.5466.8 ± 9.5861 ± 9.7765 ± 10.87
Sex: Female, Male
Sex: Female, Male(Participants)Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)Total
Female19362032107
Male48314534158
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)Total
Hispanic or Latino360716
Not Hispanic or Latino34394543161
Unknown or Not Reported3022201688
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)Total
American Indian or Alaska Native00000
Asian05005
Native Hawaiian or Other Pacific Islander00000
Black or African American512210
White38464548177
More than one race00000
Unknown or Not Reported2415181673
Region of Enrollment
Region of Enrollment(Participants)Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)D + Bortezomib + Melphalan + Prednisone (D-VMP)Daratumumab + Lenalidomide + Dexamethasone (D-Rd)Daratumumab + Carfilzomib + Dexamethasone (D-Kd)Total
BRAZIL14005
CZECH REPUBLIC4415023
FRANCE2621171579
GERMANY0001919
ISRAEL0714021
JAPAN04004
SPAIN111902555
UNITED KINGDOM9812029
UNITED STATES1607730
08

Study locations

64 sites
  • Cancer Center of Central Connecticut - Southington
    Southington, Connecticut 06489-3237, United States
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
  • UF Health Cancer Center at Orlando Health
    Orlando, Florida 32806, United States
  • Karmonos Cancer Institute
    Detroit, Michigan 48201, United States
  • Providence Cancer Center
    Southfield, Michigan 48075, United States
  • Billings Clinic
    Billings, Montana 59101, United States
  • Nebraska Hematology and Oncology
    Lincoln, Nebraska 68506, United States
  • Southeast Nebraska Cancer Center
    Lincoln, Nebraska 68510, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • NYU Winthrop
    Mineola, New York 11501, United States
  • Mt. Sinai School of Medicine
    New York, New York 10029, United States
  • Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center
    Winston-Salem, North Carolina 27157, United States
  • Avera Medical Group - Oncology & Hematology
    Sioux Falls, South Dakota 57105, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84121, United States
  • University of Virginia Cancer Center - Emily Couric Clinical Cancer Center - Women's Oncology Clinic
    Charlottesville, Virginia 22903, United States
  • Liga Norte Riograndense Contra O Cancer
    Natal, 59062 000, Brazil
  • Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo
    Passo Fundo, 99010-090, Brazil
  • Ministerio da Saude Instituto Nacional do Cancer
    Rio de Janeiro, 20230 130, Brazil
  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo
    Sao Paulo, 04037-002, Brazil
  • Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE
    Sao Paulo, 04039-004, Brazil
  • Clinica Sao Germano
    São Paulo, 01455 010, Brazil
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultni Nemocnice Ostrava
    Ostrava, 70852, Czechia
  • Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
    Praha 2, 128 08, Czechia
  • CHU de Nantes hotel Dieu
    Nantes Cedex 1, 44093, France
  • CHU de Bordeaux - Hospital Haut-Leveque
    Pessac cedex, 33604, France
  • Centre hospitalier Lyon-Sud
    Pierre-Bénite, 69495, France
  • CHU Bretonneau
    Tours Cedex 9, 37044, France
  • CHU Nancy Brabois
    Vandoeuvre Les Nancy, 54511, France
  • Klinikum Chemnitz gGmbH
    Chemnitz, 09113, Germany
  • Universitaetsklinikum Hamburg Eppendorf
    Hamburg, 20246, Germany
  • Asklepios Klinik Altona
    Hamburg, 22763, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,
    Tübingen, 72076, Germany
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Hadassah Medical Center
    Jerusalem, 9112001, Israel
  • Galilee Medical Center
    Nahariya, 22100, Israel
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Tel Aviv Sourasky Medical Center
    Tel-Aviv, 64239, Israel
  • Kanazawa University Hospital
    Kanazawa, 920 8641, Japan
  • Matsuyama Red Cross Hospital
    Matsuyama, 790-8524, Japan
  • Nagoya City University Hospital
    Nagoya, 467 8602, Japan
  • Japanese Red Cross Medical Center
    Shibuya, 150-8935, Japan
  • Inst. Cat. D'Oncologia-Badalona
    Badalona, 08916, Spain
  • Hosp Clinic de Barcelona
    Barcelona, 08036, Spain
  • Inst. Cat. Doncologia-H Duran I Reynals
    Barcelona, 08908, Spain
  • Hosp Univ Vall D Hebron
    Barcelona, 8035, Spain
  • Hosp. Gral. Univ. Gregorio Maranon
    Madrid, 28007, Spain
  • Clinica Univ. de Navarra
    Madrid, 28027, Spain
  • Hosp. Univ. Ramon Y Cajal
    Madrid, 28034, Spain
  • Hosp. Univ. 12 de Octubre
    Madrid, 28041, Spain
  • Hosp. Son Llatzer
    Mallorca, 07198, Spain
  • Clinica Univ. de Navarra
    Pamplona, 31008, Spain
  • Hosp Clinico Univ de Salamanca
    Salamanca, 37007, Spain
  • Hosp. Univ. Dr. Peset
    Valencia, 46017, Spain
  • Heart of England NHS Foundation Trust
    Birmingham, B9 5SS, United Kingdom
  • Royal Bournemouth Hospital
    Bournemouth, BH7 7DW, United Kingdom
  • Kent and Canterbury Hospital
    Canterbury, CT1 3NG, United Kingdom
  • Manchester Royal Infirmary
    Manchester, M13 9WL, United Kingdom
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
  • Royal Stoke University Hospital
    Stoke on Trent, ST4 6QG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Aug 2020, 27 months.

Results were first posted in Jan 2022, 1 year 5 months after primary completion. A results delay was requested in Aug 2021.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 27 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2018
First posted
Jan 26, 2018
StartActual
Apr 26, 2018
Primary completionActual
Aug 12, 2020
CompletionActual
Apr 18, 2024
Results delay requested
Aug 9, 2021
Results first posted
Jan 12, 2022
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03412565
Responsible party
Sponsor
First posted
Jan 26, 2018
Start date
Apr 26, 2018
Primary completion
Aug 12, 2020
Completion
Apr 18, 2024
Results posted
Jan 12, 2022
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion